Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Rita Percy, Michael E. Petrone, MD MPH, Scott Megaffin, Ayanna M Anene, BS, Jesse Ortendahl, MS, Dorothy Romanus, RPh, PhD, Tanya GK Bentley, PhD

Blood (2014) 124 (21): 1928.

https://doi.org/10.1182/blood.V124.21.1928.1928

Published: 2014

Journal Articles

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Erin P. Demakos, RN, CCRN, Lewis R. Silverman, MD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH

Blood (2014) 124 (21): 1287.

https://doi.org/10.1182/blood.V124.21.1287.1287

Published: 2014

Journal Articles

Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database

Christopher R. Cogle, MD, Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 6008.

https://doi.org/10.1182/blood.V124.21.6008.6008

Published: 2014

Journal Articles

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 2627.

https://doi.org/10.1182/blood.V124.21.2627.2627

Published: 2014

Journal Articles

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1 st -Line Therapy, Discontinuation and the Need of Additional Therapies

Sudipto Mukherjee, MD MPH, Christopher R. Cogle, MD, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 2598.

https://doi.org/10.1182/blood.V124.21.2598.2598

Published: 2014

NARROW

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1 st -Line Therapy, Discontinuation and the Need of Additional Therapies

Email alerts

ASH Publications

American Society of Hematology

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1 st -Line Therapy, Discontinuation and the Need of Additional Therapies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only